Practical points for applying herpes zoster vaccine recommendations.

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• Shingles (herpes zoster) is a common and painful condition caused by the varicella-zoster virus.
• The incidence of shingles increases with age, posing a significant health concern for older adults.
• Previous vaccination options existed, but newer recommendations prioritize more effective preventative measures.

Purpose of the Study:

• To inform clinicians about the approval and recommendation of the recombinant zoster vaccine (Shingrix).
• To provide practical guidance for the effective implementation of shingles vaccination in patients aged 50 and above.
• To highlight the CDC's updated recommendations favoring Shingrix over Zostavax.

Main Methods:

• Review of recent vaccine approval and CDC recommendations.
• Analysis of clinical considerations for vaccine administration.
• Guidance on patient counseling and management.

Main Results:

• Recombinant zoster vaccine (Shingrix) is approved for individuals aged 50 years and older.
• The CDC now recommends Shingrix over the live zoster vaccine (Zostavax).
• Practical strategies are essential for clinicians to apply these recommendations.

Conclusions:

• Shingrix represents a significant advancement in shingles prevention for older adults.
• Clinician adherence to updated guidelines is crucial for maximizing vaccine effectiveness.
• Effective patient management ensures optimal outcomes in shingles prevention programs.